Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blisibimod - Anthera Pharmaceuticals

Next Previous
Drug Profile

Blisibimod - Anthera Pharmaceuticals

Alternative Names: A-623; AMG-623; Blisibimod

Latest Information Update: 19 Feb 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Anthera Pharmaceuticals
  • Class Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - IgA nephropathy
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; IgA nephropathy; Systemic lupus erythematosus

Most Recent Events

  • 02 May 2018 Anthera Pharmaceuticals has patent protection for blisibimod in USA and Europe
  • 31 Mar 2018 Suspended - Phase-II for IgA nephropathy (Combination therapy, Treatment-experienced) in Spain, Sweden, Hungary, Italy, United Kingdom, Germany, Czech Republic, Thailand, Taiwan, Singapore, South Korea, Philippines, Malaysia, Hong Kong (SC)
  • 31 Mar 2018 Suspended - Phase-II for Systemic lupus erythematosus in Peru, Chile, Argentina, USA (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top